imatinib

Small Doses: The Weekly News You Need to Know
Small Doses: The Weekly News You Need to KnowSmall doses is a weekly slideshow of the news you may have missed, made just for you and your busy lifestyle.
Generic treatment for chronic myeloid leukemia could save millionsFive years of imatinib treatment for CML = >$100,000 saved per patient.
Cutting edge techniques provide options for skin cancerNew technologies for managing skin cancer were a topic of discussion at a scientific session at the American Society for Dermatologic Surgery’s 2015 annual meeting in Chicago in October. Seaver L. Soon, M.D., division of dermatology and dermatologic surgery at Scripps Clinic, La Jolla, Calif., was one of the moderators for the scientific discussion titled, “The Cutting Edge: New Technologies for Managing Skin Cancer.” Learn more
Cost, adherence as vital as TKI choice for CMLPrice, comorbidities are as important as TKI choice for patients with chronic myeloid leukemia
ASH: 6-year data reinforce superiority of nilotinib over imatinib in newly-diagnosed patients with Ph+ CMLNilotinib (Tasigna) should be considered as a leading option for front-line therapy in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), according to data presented at the 56th ASH Annual Meeting and Exposition in San Francisco.
Four-year update shows nilotinib induces significantly deeper molecular responses than imatinibThe 4-year data from the landmark ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials – Newly Diagnosed Patients) trial continues to demonstrate the improved clinical benefit of front-line nilotinib (Tasigna) versus imatinib (Gleevec) in patients with newly diagnosed, Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase
Nilotinib leads to sustained responses in CML patients with residual disease on imatinibFor chronic myeloid leukemia (CML) patients with minimal residual disease on long-term imatinib (Gleevec) therapy, switching to nilotinib (Tasigna) can lead to deep, sustained responses.